Back to Authors

Ho, Thai H.

https://orcid.org/0000-0003-0023-2939

Mayo Clinic

Medical University of South Carolina

Citations 113

A molecular and clinico-pathological model for predicting abiraterone acetate/prednisone (AA/P) efficacy in metastatic castrate resistant prostate cancer (mCRPC).
Qin, Rui , Sicotte, Hugues , Carlson, Rachel E. , Tan, Winston , Jiménez, Rafael E. , Wang, Liewei , Eckel‐Passow, Jeanette E. , Costello, Brian A. , Pitot, Henry C., Dronca, Roxana , Wu, Kevin J. , Moynihan, Timothy J. , Atwell, Thomas D. , McMenomy, Brendan P., Kohli, Manish , Wang, Liguo , Quevedo, Fernando , Ho, Thai H. , Bryce, Alan H. , Dehm, Scott M.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5056-5056

10.1200/jco.2015.33.15_suppl.5056 Get It

Clinical impact of loss of H3K36me3 expression in patients with clear cell renal cell carcinoma.
Swaika, Abhisek, Serie, Daniel, Eckel‐Passow, Jeanette E. , Parker, Alexander S. , Ho, Thai H. , Kapur, Payal , Brugarolas, James , Joseph, Richard W.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4563-4563

10.1200/jco.2015.33.15_suppl.4563 Get It

Molecular analysis of sarcomatoid renal cell carcinoma (sRCC).
Millis, Sherri Z. , Bryant, David , Gatalica, Zoran , Stanton, Melissa, Castle, Erik P., Ho, Thai H. , Reddy, Sandeep K. , Joseph, Richard W. , Vogelzang, Nicholas J.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4556-4556

10.1200/jco.2015.33.15_suppl.4556 Get It

Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Barrios, Pablo M. , Albigès, Laurence , Krajewski, Katherine M. , Pal, Sumanta K. , Heng, Daniel Yick Chin, Kwiatkowski, David J. , Thorner, Aaron R. , Rini, Brian I. , Agarwal, Neeraj , Ho, Thai H. , Van Allen, Eliezer M , Porta, Camillo , Bellmunt, Joaquim , McDermott, David F. , Signoretti, Sabina , Choueiri, Toni K.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4519-4519

10.1200/jco.2015.33.15_suppl.4519 Get It

Prognostic impact of peripheral blood counts in patients with non-metastatic clear cell renal cell carcinoma.
Hammond, William A. , Hassan, Lauren, Serie, Daniel, Eckel‐Passow, Jeanette E. , Leibovich, Bradley C. , Thompson, R. Houston, Cheville, John C. , Parker, Alexander S. , Hammond, William Adam, Lewis, Daniel, Ho, Thai H. , Joseph, Richard W.

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15590-e15590

10.1200/jco.2015.33.15_suppl.e15590 Get It

Role of robot assisted retroperitoneal lymph node dissection in metastatic malignant mesothelioma of the tunica vaginalis: Case series.
Abdul‐Muhsin, Haidar , Navaratnam, Anojan , Singh, Parminder , Cheney, Scott, Tyson, Mark D. , Castle, Erik P., Faraj, Kassem , Rose, Kyle , Ho, Thai H. , Bryce, Alan H.

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 536-536

10.1200/jco.2019.37.7_suppl.536 Get It

536 Background: The management of malignant mesothelioma of the tunica vaginalis of the testes (MMTVT) is not clearly defined, though retroperitoneal lymph node dissection has been reported as a diagnostic and potentially therapeutic option. Herein we present our experience with robot assisted retroperitoneal lymph node dissection (RARPLND) in a series of patients with MMTVT. Methods: The Mayo Clinic cancer registry was queried from 1972-present for all patients who had a diagnosis of MMTVT. Six patients were identified, five of whom were treated with RPLND, where four underwent RARPLND. Data was collected on pertinent demographic, preoperative, perioperative, postoperative outcomes and follow-up oncological data. Results: In five patients who underwent RPLND, the median age was 50 years (IQR 34-51), median BMI was 26.9 (IQR 26.4-30.6). Four patients originally presented with right sided symptomatic hydroceles, while one presented with right sided chronic epididymitis. Orchiectomy (one simple, two inguinal radical) was performed in three patients and hydrocelectomy in the other two patients prior to presentation. Preoperative cross-sectional imaging, including PET-CT scan in three patients, was negative for lymphadenopathy or metastasis. RARPLND was performed in 4/5 (80%) cases and concomitant hemiscrotectomy in 4/5 (80%) cases. Full bilateral template was performed in three patients and right modified template was performed in the remaining two. Median lymph node yield was 29 (IQR 22-32) and median blood loss was 275 cc (IQR 200-300). Positive retroperitoneal lymph nodes were found in 3/5 (60%) cases. Final margins of hemiscrotectomy were negative in all four cases. All patients who underwent RARPLND were discharged home on postoperative day one. One patient received four cycles of adjuvant Cisplatin and Pemetrexed. Mean follow-up was 27 months (range 2-47). No patients recurred. Conclusions: MMTVT is a very rare malignancy with high potential for retroperitoneal lymph node dissemination. Regardless of the approach, RPLND may provide both a diagnostic and therapeutic benefit, with the robotic approach affording a potentially expedited recovery.
The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ.
D’Amelio, Anthony M., Hsieh, James J. , Souza, Paul L. de , Deen, Keith C., Langmuir, Peter, Liu, Yuan , Ho, Thai H. , Choueiri, Toni K. , Motzer, Robert J.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4583-4583

10.1200/jco.2014.32.15_suppl.4583 Get It

Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial).
Costello, Brian A. , Tan, Winston , Leibovich, Bradley C. , Castle, Erik P., Parker, Alexander S. , Dronca, Roxana , Qin, Rui , Ho, Thai H. , Kohli, Manish

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS4606-TPS4606

10.1200/jco.2014.32.15_suppl.tps4606 Get It

Loss of BAP1 and PBRM1 expression in non-clear cell renal cell carcinomas compared to clear cell renal cell carcinomas.
Serie, Daniel, Eckel‐Passow, Jeanette E. , Parasramka, Mansi, Cheville, John C. , Parker, Alexander S. , Ho, Thai H. , Kapur, Payal , Joseph, Richard W. , Brugarolas, James

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4529-4529

10.1200/jco.2014.32.15_suppl.4529 Get It

PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors.
Fay, André P. , Gray, Kathryn P. , Song, Jiaxi , Carvo, Ingrid, Lampron, Megan E., Albigès, Laurence , Stanton, Melissa, Freeman, Gordon J. , Hirsch, Michelle S. , Callea, Marcella , Ho, Thai H. , McDermott, David F. , Atkins, Michael B. , Signoretti, Sabina , Choueiri, Toni K.

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4526-4526

10.1200/jco.2014.32.15_suppl.4526 Get It